Law360 (May 20, 2004, 12:00 AM EDT) -- Israeli generic drug maker Teva Pharmaceutical Industries plans to continue selling its version of Abbott Laboratories' pain medication vicoprofen, despite losing an appeal in a patent dispute.
Teva said the U.S. Court of Appeals for the Federal Circuit has vacated a September 2002 summary judgment which invalidated the patent protecting vicoprofen.
The district court had ruled that the U.S. patent was invalid as obvious, but the Federal Circuit disagreed with the lower court.
“Although the prior art appears to suggest combining an opioid, such as hydrocodone,...
Teva To Continue Selling Generic Vicoprofen After Losing Vs. Abbott At Federal Circuit
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
